Pei-Ling Chu

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 5.7K citations · Full text

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 84 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

A1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial)

David S. Oyer, Mark D. Shepherd, Franklin C. Coulter et al. · The American Journal of Medicine · 2009 · 44 citations

Diabetes Management, Primary Care, Health Policy +6

Unifying CRM and EWOC designs for phase I cancer clinical trials

Pei-Ling Chu, Yong Lin, Weichung Joe Shih · Journal of Statistical Planning and Inference · 2008 · 42 citations

Medicine, Cancer Management, Clinical Endpoint +11

Therapeutic Effect of HGF on NASH Mice Through HGF/c-Met and JAK2-STAT3 Signalling Pathway

Ning Li, Zhangfeng Dou, Jinchun Liu et al. · Annals of Hepatology · 2018 · 27 citations · Full text